Drugs / Uprifosbuvir
Uprifosbuvir
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02666352 | Jan 2016 → Jan 2017 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02661126 | Jan → Aug 2016 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01974687 | Oct 2013 → Sep 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02956629 | Nov 2016 → Dec 2017 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02759315 | May 2016 → Jul 2017 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02613403 | Dec 2015 → Jan 2017 | Flaviviridae infectious disease, hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02332720 | Jan 2015 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02332707 | Jan 2015 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uprifosbuvir | “This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR [MK-5172]; 100mg), uprifosbuvir (UPR [MK-3682]; 450 mg) and ruzasvir...” NCT02613403 ↗7“FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.” NCT02661126 ↗ |
| Known as | IDX21437 | “225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR)” NCT02613403 ↗ |
| Known as | MK-3682 | “The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) +...” NCT02661126 ↗1“uprifosbuvir (UPR [MK-3682]; 450 mg)” NCT02613403 ↗ |
| Known as | UPR | “In clinical trials, the three-drug regimen of ruzasvir (RZR) 60 mg, uprifosbuvir (UPR) 450 mg and grazoprevir 100 mg, with or without ribavirin, has demonstrated promising...” PMID 30739366 ↗ Mar 20191“uprifosbuvir (UPR [MK-3682]; 450 mg)” NCT02613403 ↗ |
| Action | Inhibit | “uprifosbuvir (MK-3682; an HCV NS5B polymerase inhibitor; 450 mg/day)” PMID 28802814 ↗ Aug 2017 |
| Modality | Other / unclassified | “uprifosbuvir (MK-3682, a nonstructural protein 5B nucleotide inhibitor) are highly potent direct-acting antiviral agents” PMID 31108015 ↗ Jul 2019 |
| Route | Oral | “administered by mouth.” NCT01974687 ↗ |